Compare AGBK & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGBK | SLDB |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | Brazil | United States |
| Employees | N/A | 121 |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 932.9M |
| IPO Year | 2025 | 2017 |
| Metric | AGBK | SLDB |
|---|---|---|
| Price | $5.88 | $7.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $17.20 | $16.36 |
| AVG Volume (30 Days) | 155.2K | ★ 948.7K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $235.22 | N/A |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.73 | $3.79 |
| 52 Week High | $12.21 | $11.45 |
| Indicator | AGBK | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 30.15 |
| Support Level | N/A | $6.38 |
| Resistance Level | $7.42 | $8.12 |
| Average True Range (ATR) | 0.21 | 0.50 |
| MACD | -0.07 | -0.22 |
| Stochastic Oscillator | 10.14 | 4.93 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.